|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current status and perspectives of immune-based therapiesfor hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC)is a frequent cancer with a high mortality.For early stage cancer there are potentially curative treatments including local ablation,resection and liver transplantation.However,for more advanced stage disease,there is no optimal treatment available.Even in the case of a'curative'treatment,recurrence or development of a new cancer in the precancerous liver is common.Thus,there is an urgent need for novel and effective(adjuvant)therapies to treat HCC and to prevent recurrence after local treatment in patients with HCC.The unique immune response in the liver favors tolerance,which remains a genuine challenge for conventional immunotherapy in patients with HCC.However,even in this'immunotolerant'organ,spontaneous immune responses against tumor antigens have been detected,although they are insufficient to achieve significant tumor death.Local ablation therapy leads to immunogenic tumor cell death by inducing the release of massive amounts of antigens,which enhances spontaneous immune response.New immune therapies such as dendritic cell vaccination and immune checkpoint inhibition are under investigation.Immunotherapy for cancer has made huge progress in the last few years and clinical trials examining the use of immunotherapy to treat hepatocellular carcinoma have shown some success.In this review,we discuss the current status of and offer some perspectives on immunotherapy for hepatocellular carcinoma,which could change disease progression in the near future. | Maridi Aerts DaphnéBenteyn Hans Van Vlierberghe Kris Thielemans Hendrik Reynaert | 2016 | World Journal of Gastroenterology2016，22，1： | 24 |
| 2 | Dendritic cells loaded with mRNA encoding full-length tumor anti- gens prime CD4 +and CD8+ T cells in melanoma patients 显示文摘 | Van Nuffel AM Benteyn D Wilgenhof S | 2012 | Mol Ther2012，20，5： | 1 |
| 3 | mRNA-based dendritic cell vaccines 显示文摘 | BENTEYN D HEIRMAN C BONEHILL A | 2014 | Expert Rev Vaccines2014，14，2： | 1 |
| 4 | Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-Mle melanoma patient 显示文摘 | Van Nuffel AM Benteyn D Wilgenhof S | 2012 | Cancer Immunol Immunother2012，61，7： | 1 |
| 5 | A phase I B study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients 显示文摘 | Wilgenhof S Van Nuffel A M Benteyn D | 2013 | Ann Oncol2013，24，10： | 1 |
| 6 | Intravenous and intradennal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-Mlc melanoma patient 显示文摘 | Van Nuffel A M Benteyn D Wflgenhof S | 2012 | Cancer Immunol Inmaunother2012，61，7： | 1 |
| 7 | Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients显示文摘 | Van Nuffel AM Benteyn D Wilgenhof S | | 0，，05： | 1 |
| 8 | Therapeutic vacci- nation with autologous mRNA electroporated dendritic cells ( DC ) in patients With Advanced Melanoma 显示文摘 | Wilgenhof S Van Nuffel A Benteyn D | 2010 | J Immunother2010，33，8： | 1 |
| 9 | intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage 1V -Mlc melanoma patient 显示文摘 | Van Nuffel AM Benteyn D Wilgenhof S | 2012 | Cancer Immunol Immunother2012，61，7： | 1 |
| 10 | A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immun- otherapy in pretreated advanced melanoma patients显示文摘 | Wilgenhof S Van Nuffel AM Benteyn D | 2013 | Ann Oncol2013，24，10： | 1 |
| 11 | mRNA-based :lendritic cell vaccines显示文摘 | Benteyn D Heirman C Bonehill A | 2015 | Expert Rev Vaccines2015，14，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员